The ability of β-Catenin to cooperate with other oncogenic events such as Pten deletion, mutant K-ras and SV40 large T-antigen to drive tumour progression suggests that it may be a general drug target in prostate cancer [28], [29]. The gene discussed is KRAS; the disease is prostate cancer.